title: [Clinical and prognostic significance of the doubling time of initial prostate-specific antigen in patients with prostate cancer].
abstract: Kinetic parameters of prostate-specific antigen (PSA) play a pivotal role in diagnostic and treatment of patients with prostate cancer (PCr). Assessment of PSA doubling time (PSADT) can be used for monitoring of treatment efficacy and predicting the outcomes of disease. The aim of the present paper is to analyze the PSADT in patients with different spread of PCr. Moreover, the initial PSADTs were studied with relation to overall survival. 336 PCr patients were included into the study. PSADT was measured usng two point method. Ill patients had localized PCr (T1-2N0M0), 90--regional-local PCr (T1-2N0M0) and 136 had generalized PCr (T1-4N1-2M1).
  
  
  RESULTS
  Median PSADT in patients with generalized PCr amounted to 2,93 months and was significantly lower as compared to groups of patients with local and regional-local spread of disease--15,2 and 13,2 months respectively. Follow-up results revealed the link between PSADT and survival rates: the lower is PSADT, the worse are survival rates.
authors.forename: G M
authors.initials: GM
authors.lastname: Zharinov
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Neklasova
authors.forename: A A
authors.initials: AA
authors.lastname: Zimin
mesh_terms: D000368:Aged; D018450:Disease Progression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen